TUESDAY, March 2, 2021 (HealthDay News) -- Individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection generate strong responses to one dose of the BNT162b2 vaccine, according to two research letters published online Feb. 25 in The Lancet. Maria Prendecki, Ph.D., from Imperial College London, and colleagues investigated immunological responses...
Read Full StoryIf the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com
comments